Filing Analysis
BioSig Technologies, Inc. held its 2024 annual meeting where stockholders approved a proposal authorizing the Board to execute a reverse stock split at a ratio between 1-for-2 and 1-for-10. The meeting also resulted in the election of five directors and the ratification of Marcum LLP as auditors.
🚩 Red Flags
- Approval of a reverse stock split (1-for-2 to 1-for-10) is often used to combat delisting notices or low share prices.
- Significant increase in authorized shares under the Incentive Plan (3.5M additional shares) may lead to future dilution.
📋 Key Facts
- Stockholders approved a Reverse Stock Split Proposal with 8,666,835 votes 'For' and 918,208 'Against'.
- The reverse split ratio is to be determined by the Board within a range of 1-for-2 to 1-for-10.
- Stockholders approved an amendment to increase the total number of shares authorized under the Incentive Plan by 3,500,000 to a total of 4,376,595 shares.
- Five directors were elected: Anthony Amato, Frederick D. Hrkac, Christopher A. Baer, Donald F. Browne, and Steven E. Abelman.
- Marcum LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
BioSig Technologies, Inc. entered into an At-The-Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $8.5 million of common stock. The proceeds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to address immediate liquidity needs or cash burn issues.
📋 Key Facts
- Entered into Sales Agreement with H.C. Wainwright & Co., LLC on December 18, 2024.
- Aggregate offering amount: up to $8,500,000 of common stock.
- The offering is being conducted under a shelf registration statement (Form S-3) declared effective by the SEC on December 17, 2024.
- Agent (H.C. Wainwright & Co., LLC) will receive a 3% cash commission on gross sales.
- Proceeds are designated for working capital and general corporate purposes.
BioSig Technologies, Inc. announced that a Minnesota District Court has granted its motion to dismiss a lawsuit filed by Michael Gray Fleming. The lawsuit sought $288,000 in damages regarding alleged failure to issue restricted stock awards.
🚩 Red Flags
- None identified; this is a favorable legal outcome for the company.
📋 Key Facts
- The lawsuit was originally filed on March 22, 2024, in Hennepin County, Minnesota District Court.
- Plaintiff Michael Gray Fleming sought at least $288,000 in damages.
- Defendants included the Company and its former CEO and CFO.
- The court issued an Order Granting Motion to Dismiss on December 3, 2024.
BioSig Technologies, Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company was previously notified of a deficiency but successfully maintained a closing bid price of $1.00 or greater for 10 consecutive business days.
🚩 Red Flags
- Historical delisting risk: The company was recently in violation of Nasdaq's minimum bid price requirement.
📋 Key Facts
- Nasdaq Staff notified the company on October 24, 2024, regarding failure to maintain a minimum bid price of $1.00.
- The company achieved compliance by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days (Oct 30, 2024 - Nov 12, 2024).
- Nasdaq has officially closed the matter regarding Listing Rule 5550(a)(2) compliance.
- The company issued a press release on November 13, 2024, to announce the regained compliance.
BioSig Technologies, Inc. received a deficiency notice from Nasdaq because its common stock failed to maintain the minimum $1.00 bid price requirement over a specified period ending October 23, 2024. The company has been granted a 180-day compliance period to regain compliance by achieving a $1.00 closing bid price for ten consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq (non-compliance with minimum bid price).
- Explicit mention of potential requirement for a reverse stock split to maintain listing.
- Historical stock price performance has been insufficient to maintain the $1.00 threshold.
📋 Key Facts
- Received Nasdaq deficiency notice on October 24, 2024.
- Failure to meet the minimum $1.00 per share bid price requirement based on closing prices from June 11, 2024, through October 23, 2024.
- The company has a 180-calendar-day compliance period to regain compliance.
- Compliance can be achieved if the stock closes at $1.00 or higher for ten consecutive business days.
- If compliance is not met within the initial period, the company may need to effect a reverse stock split to meet listing requirements.
BioSig Technologies received a grace period from the Nasdaq Listing and Hearing Review Council to regain compliance with the Minimum Market Value of Listed Securities (MVLS) rule. The company must meet the $35 million market value requirement by March 7, 2025.
🚩 Red Flags
- Non-compliance with Nasdaq's Minimum Market Value of Listed Securities (MVLS) rule.
- Requirement to reach a $35 million market cap by March 7, 2025, poses significant liquidity and valuation risk for a micro-cap company.
📋 Key Facts
- Nasdaq Listing and Hearing Review Council granted a grace period until March 7, 2025.
- The compliance requirement is Nasdaq Listing Rule 5550(b)(2) (MVLS Rule).
- The MVLS rule requires the market value of listed securities to be at least $35 million.
- Common stock will commence trading on The Nasdaq Stock Market effective October 23, 2024.
BioSig Technologies, Inc. has appointed its current CEO, Anthony Amato, as Chairman of the Board following the resignation of Kenneth L. Londoner. The filing also details a new executive employment agreement for Mr. Amato effective August 1, 2024.
🚩 Red Flags
- Significant equity compensation package (over 3.9 million total shares/options) for the CEO in a micro-cap context.
- Substantial severance provisions including double-trigger change of control protections and 18 months of health insurance coverage.
📋 Key Facts
- Anthony Amato (CEO) appointed as Chairman of the Board on September 11, 2024.
- Kenneth L. Londoner resigned as Chairman (previously announced February 27, 2024).
- New Executive Employment Agreement for Mr. Amato effective August 1, 2024.
- Annual base salary set at $300,000 with a 60% discretionary bonus eligibility.
- Grant of 2,400,000 stock options with an exercise price of $0.4479 per share.
- Grant of 275,000 fully vested restricted shares and 1,275,000 time-based restricted shares to Mr. Amato.
BioSig Technologies, Inc. has commenced trading on the OTCQB following a suspension of its Nasdaq listing. The company is currently appealing the Nasdaq delisting decision to the Listing and Hearing Review Council.
🚩 Red Flags
- Delisted from Nasdaq (primary exchange) as of June 12, 2024.
- Trading moved to OTCQB, which typically results in significantly lower liquidity and higher volatility for micro-cap stocks.
- Ongoing legal/regulatory uncertainty regarding the appeal process with the Nasdaq Listing and Hearing Review Council.
📋 Key Facts
- Commenced trading of common stock on the OTCQB (operated by OTC Markets Group, Inc.) on July 23, 2024.
- Nasdaq trading was suspended effective June 12, 2024, following a delisting decision on June 10, 2024.
- The company filed an appeal to the Nasdaq Listing and Hearing Review Council on July 10, 2024.
- Currently awaiting a decision regarding the appeal of the delisting.
BioSig Technologies, Inc. was notified that the Nasdaq Hearings Panel declined to reconsider its decision to delist the company's common stock. Trading on Nasdaq has been suspended as of June 12, 2024, and the company is currently appealing the decision to the Nasdaq Listing and Hearing Review Council.
🚩 Red Flags
- Delisting notice from a major exchange (Nasdaq).
- Trading suspension on primary exchange.
- Downgrade to OTC Pink tier reduces liquidity and institutional visibility.
📋 Key Facts
- Nasdaq Hearings Panel declined to reconsider the June 10, 2024 delisting decision on June 24, 2024.
- Trading of common stock was suspended on Nasdaq effective at the open of business on June 12, 2024.
- Securities are currently eligible to trade on the OTC Market's Pink Current Information tier.
- The company is seeking approval to trade on the OTCQB platform.
- On June 25, 2024, the company appealed the determination to the Nasdaq Listing and Hearing Review Council.
BioSig Technologies, Inc. has received formal notice from the Nasdaq Hearings Panel to delist its common stock due to failure to meet minimum stockholders' equity requirements. Trading on Nasdaq is scheduled to be suspended effective June 12, 2024.
🚩 Red Flags
- Delisting notice (Nasdaq)
- Failure to meet minimum stockholders' equity requirements
- Imminent suspension of trading on a major exchange (Nasdaq) moving to OTC Pink
- Uncertainty regarding the success of appeals or ability to satisfy Nasdaq conditions
📋 Key Facts
- Nasdaq Hearings Panel determined delisting due to non-compliance with Nasdaq Listing Rule 5550(b)(2) (minimum stockholders' equity).
- Trading on Nasdaq is scheduled for suspension effective at the open of business on Wednesday, June 12, 2024.
- Common stock is expected to move to OTC Markets 'Pink Current Information' tier under symbol 'BSGM' starting June 12, 2024.
- The Company intends to seek reconsideration from the Panel and appeal to the Nasdaq Listing and Hearing Review Council.
BioSig Technologies, Inc. announced the resignation of its acting CFO and principal accounting officer, Frederick D. Hrkac, effective June 5, 2024. The company has appointed Ferdinand Groenewald as interim CFO, principal accounting officer, and VP of Finance via a new consulting agreement.
🚩 Red Flags
- Sudden departure of the acting CFO/Principal Accounting Officer.
- Transition from an 'acting' officer to a 'consultant' rather than a full-time permanent hire may indicate ongoing financial instability or cost-cutting measures.
📋 Key Facts
- Frederick D. Hrkac resigned as acting CFO and principal accounting officer on June 5, 2024.
- Ferdinand Groenewald appointed as interim CFO, principal accounting officer, and VP of Finance effective June 5, 2024.
- Groenewald's compensation is set at a fixed rate of $15,000 per month plus expense reimbursement.
- The consulting agreement for Groenewald has no fixed end date and requires 30 days' notice for termination.
BioSig Technologies, Inc. completed a combined registered direct offering and private placement on May 30, 2024, raising approximately $3.0 million in gross proceeds. The offering included the issuance of common stock at $1.91 per share and warrants with an exercise price of $1.78 per share.
🚩 Red Flags
- Significant dilution potential from both common stock issuance and warrants (1:1 warrant coverage).
- Warrant exercise price ($1.78) is below the current offering price ($1.91), creating immediate downside pressure upon exercise.
- High cost of capital including 8% in fees to placement agent plus various expense reimbursements.
- Forward-looking statements explicitly mention risks regarding Nasdaq listing compliance and cash burn reduction targets.
📋 Key Facts
- Raised gross proceeds of approximately $3.0 million on May 30, 2024.
- Issued 1,570,683 shares of Common Stock at $1.91 per share via a registered direct offering.
- Issued Private Placement Warrants for up to 1,570,683 shares at an exercise price of $1.78 per share.
- H.C. Wainwright & Co., LLC acted as placement agent with an 8% total fee (7% cash, 1% management).
- Issued Agent Warrants for 109,948 shares at an exercise price of $2.3875 per share.
- The company is subject to a 60-day non-issuance restriction on new equity following the offering.
BioSig Technologies, Inc. received a decision from the Nasdaq Hearings Panel granting continued listing, contingent upon meeting specific compliance requirements by June 6, 2024.
🚩 Red Flags
- Delisting risk: The company is currently under scrutiny regarding listing requirements.
- Tight timeline: Compliance must be evidenced by June 6, 2024, providing a very narrow window for capital infusion or restructuring.
- Equity deficiency: The requirement to meet the $2.5 million stockholders' equity threshold suggests current equity levels are below this mandate.
📋 Key Facts
- The Nasdaq Hearings Panel granted a request for continued listing subject to conditions.
- The Company must comply with all applicable Nasdaq Capital Market criteria.
- A critical requirement is maintaining at least $2.5 million in stockholders' equity (Nasdaq Listing Rule 5550(b)(1)).
- The deadline for demonstrating compliance is June 6, 2024.
BioSig Technologies, Inc. announced the appointment of several independent directors to its various board committees effective May 20, 2024.
📋 Key Facts
- Steven E. Abelman appointed as chairman of the Audit Committee and member of Compensation and Nominating/Corporate Governance Committees.
- Donald F. Browne appointed as chairman of the Compensation and Nominating/Corporate Governance Committees and member of the Audit Committee.
- Chris Baer appointed as a member of the Audit, Compensation, and Nominating/Corporate Governance Committees.
- Directors will receive compensation consistent with market practices and the Company's non-employee director compensation policy.
BioSig Technologies has regained compliance with Nasdaq's minimum bid price requirement after trading above $1.00 for 20 consecutive days. However, the company remains non-compliant regarding market value of listed securities and board requirements, and a delisting hearing is still scheduled for May 7, 2024.
🚩 Red Flags
- Continued non-compliance with market value of listed securities requirement.
- Ongoing delisting risk despite regaining bid price compliance.
- Non-compliance with independent board and committee requirements.
- Company is ineligible for a second 180-day cure period due to failing the $5M minimum stockholders' equity requirement.
📋 Key Facts
- Regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price requirement).
- Compliance achieved by closing at or above $1.00 per share for 20 consecutive business days from April 8, 2024, to May 3, 2024.
- Company remains non-compliant with Nasdaq market value of listed securities requirements.
- Company remains non-compliant with public shell and independent board/committee requirements.
- A hearing before the Nasdaq Hearings Panel is scheduled for May 7, 2024.
BioSig Technologies entered into a Securities Purchase Agreement on May 1, 2024, to raise capital through the sale of common stock and warrants. The transaction involves both new cash infusion and the conversion of an existing $500,000 promissory note.
🚩 Red Flags
- Significant portion of financing ($509k) is a debt conversion rather than new cash, indicating the company is servicing existing obligations by issuing equity.
- The use of warrants with an exercise price below current issuance price suggests potential future dilution.
📋 Key Facts
- Total consideration: $1,144,164.46
- Cash component: $634,999.11
- Debt conversion component: $509,165.35 (principal and accrued interest from a 12% Note due 2026)
- Shares issued: 783,406 shares of common stock at $1.4605 per share
- Warrants issued: Up to 391,703 warrants with an exercise price of $1.398 per share
- Warrant terms: Exercisable six months after issuance; expires 5.5 years from issuance
BioSig Technologies, Inc. announced the appointment of three new independent directors to its Board: Steven E. Abelman, Donald F. Browne, and Chris Baer. This move results in a fully constituted Board of Directors.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Appointed Steven E. Abelman as an independent director on May 3, 2024; expert in commercial litigation and bankruptcy law.
- Appointed Donald F. Browne, C.P.A., as an independent director on May 3, 2024; specialist in business accounting and tax reporting.
- Confirmed the appointment of Chris Baer as a director (previously announced on May 2, 2024).
- All three new appointees qualify as independent directors under NASDAQ Listing Rules.
- The appointments are for terms expiring at the next annual meeting or until successors are elected.
BioSig Technologies, Inc. announced a leadership transition effective April 30, 2024, appointing Anthony Amato as President and CEO. Concurrently, Mr. Hrkac resigned from his role as President and Principal Executive Officer but will remain on the Board and serve as acting CFO.
🚩 Red Flags
- Management instability: Simultaneous departure of the President/CEO and appointment of an acting CFO suggests potential internal reorganization or volatility.
- The CEO is moving from a consultant/advisory role directly to the top executive position, which can sometimes indicate rapid shifts in company direction.
📋 Key Facts
- Anthony Amato appointed as Director, President, CEO, and Principal Executive Officer effective April 30, 2024.
- Mr. Hrkac resigned as President and Principal Executive Officer effective April 30, 2024.
- Mr. Hrkac will continue to serve as a director and acting Chief Financial Officer (CFO).
- Anthony Amato previously served on the advisory board from January 2021 to February 2024 and as a consultant since March 2024.
BioSig Technologies, Inc. announced the appointment of Chris Baer to its Board of Directors on May 2, 2024. Mr. Baer brings extensive commercial experience in the medical device and electrophysiology sectors.
📋 Key Facts
- Appointment date: May 2, 2024
- Appointee: Chris Baer (Age 55)
- Role: Director and member of Audit, Nominating, and Compensation committees
- Professional Background: Currently Chief Commercial Officer at CDL Nuclear Technologies; formerly VP of Commercial Operations at Impulse Dynamics and leadership roles at St. Jude Medical / Abbott.
- Term: Until the next annual meeting or until successor is elected/qualified.
BioSig Technologies is facing imminent delisting from the Nasdaq Capital Market after being designated a 'public shell' by Nasdaq Staff. The company has appealed the determination and has a hearing scheduled for May 7, 2024.
🚩 Red Flags
- Designation as a 'public shell' by Nasdaq Staff
- Extreme loss of human capital (only 1 employee remains)
- Massive board and management exodus
- Failure to meet minimum bid price and stockholders' equity requirements
- Imminent delisting threat
📋 Key Facts
- Nasdaq Staff believes the Company no longer has an operating business and is a 'public shell'.
- The Company failed to meet the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
- The Company does not comply with the $5,000,000 minimum stockholders' equity requirement.
- Significant workforce reduction occurred on Feb 5, 2024, including the COO and CCO.
- Major leadership turnover: CFO resigned; CEO Kenneth Londoner resigned; 6 of 7 directors resigned.
- As of the filing, the Company has only one employee and one board member remaining.
- Nasdaq hearing scheduled for May 7, 2024.
BioSig Technologies, Inc. issued a $500,000 promissory note to an investor on March 7, 2024. The note carries a 12% annual interest rate and is due in full on March 7, 2026.
🚩 Red Flags
- Debt issuance for a relatively small amount ($500k) often indicates immediate liquidity needs or working capital requirements in micro-cap companies.
- High interest rate (12%) suggests the company may be facing higher risk profiles from lenders.
📋 Key Facts
- Issued a Promissory Note for $500,000 principal amount.
- Interest rate is 12% per annum, payable in cash.
- Maturity date is March 7, 2026.
- The note was issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933.
BioSig Technologies, Inc. has received a delisting notice from Nasdaq after failing to regain compliance with the minimum bid price requirement and failing to meet the $5,000,000 minimum stockholders' equity requirement. The company has filed an appeal to request a hearing before the Nasdaq Hearings Panel.
🚩 Red Flags
- Delisting notice received from Nasdaq
- Failure to meet minimum stockholders' equity requirement ($5M)
- Ineligibility for a second compliance period
- Ongoing uncertainty regarding ability to maintain exchange listing
📋 Key Facts
- Nasdaq issued a delisting notice on March 5, 2024, after the company failed to regain compliance with Rule 5810(c)(3)(A).
- The company failed both the minimum bid price requirement ($1.00) and the $5,000,000 minimum stockholders' equity initial listing requirement.
- The company is ineligible for a second 180-day compliance period under Rule 5810(c)(3)(A)(2).
- On March 11, 2024, the company submitted a request for a hearing before the Nasdaq Hearings Panel to appeal the determination.
- The stock continues to trade on the Nasdaq Capital Market under symbol 'BSGM' pending the outcome of the appeal.
BioSig Technologies, Inc. announced a significant leadership transition effective February 27, 2024. Kenneth L. Londoner resigned from all roles including CEO and Executive Chairman, while Frederick D. Hrkac was appointed as Director, President, and Principal Executive Officer.
🚩 Red Flags
- Sudden departure of the CEO and Executive Chairman simultaneously.
- Leadership vacuum created by a single individual (Hrkac) assuming multiple top-tier roles (Director, President, and PEO).
📋 Key Facts
- Kenneth L. Londoner resigned as Director, Executive Chairman, and CEO effective February 27, 2024.
- Frederick D. Hrkac appointed as Director, President, and Principal Executive Officer effective February 27, 2024.
- The company stated Mr. Londoner's resignation was not due to any disagreement regarding operations, policies, or practices.
BioSig Technologies, Inc. experienced a massive leadership exodus involving the resignation of its CFO and six members of the Board of Directors within a single week in February 2024.
🚩 Red Flags
- Massive board turnover: 6 directors resigning simultaneously is highly unusual for a stable micro-cap.
- CFO departure: Loss of key financial leadership often precedes reporting delays or internal control issues.
- Multiple items in a single filing (Item 5.02): Indicates a period of significant organizational instability.
📋 Key Facts
- CFO Steve Buhaly resigned effective February 15, 2024.
- Four directors (David Weild IV, Donald E. Foley, Patrick J. Gallagher, and James J. Barry) resigned effective February 19, 2024.
- Two additional directors (James L. Klein and Frederick D. Hrkac) resigned effective February 20, 2024.
- The company stated that none of the resignations were due to disagreements regarding operations, policies, or practices.
BioSig Technologies, Inc. issued a press release announcing that physicians have completed over 100 cases utilizing the company's Near Field Tracking algorithm. This filing is made under Item 7.01 (Regulation FD Disclosure) and does not constitute material non-public information.
📋 Key Facts
- Physicians have completed over 100 cases using the Near Field Tracking algorithm as of February 6, 2024.
- The announcement was made via a press release attached as Exhibit 99.1.
- The filing is provided under Item 7.01 to satisfy Regulation FD requirements.
BioSig Technologies, Inc. (BSGM) has announced a significant workforce reduction involving 16 employees, including the COO and CCO, to reduce annual cash burn by approximately 50%. The filing is an amendment to correct previous errors regarding unexecuted consulting agreements.
🚩 Red Flags
- Significant reduction in force (16 employees) including key C-suite executives.
- High cost of restructuring ($713,924) relative to micro-cap scale.
- Heavy use of equity for retention bonuses ($578,636), indicating potential dilution and cash constraints.
- Correction of previous filing (Amendment 1/A) regarding unexecuted agreements suggests internal control or communication issues.
📋 Key Facts
- Workforce reduction of 16 employees completed as of January 31, 2024.
- Departure of Chief Operating Officer (John Sieckhaus) and Chief Commercial Officer (Gray Fleming).
- Estimated total aggregate costs for the reduction: ~$713,924.
- Breakdown of costs includes $135,288 in severance/departure fees and $578,636 in retention bonuses paid in equity.
- The company aims to reduce annual cash burn by approximately 50%.
- Amendment filed to correct the Original Form 8-K regarding unexecuted consulting agreements.
BioSig Technologies, Inc. has executed a significant workforce reduction involving 16 employees to reduce annual cash burn by approximately 50%. The restructuring includes the departure of both the Chief Operating Officer and the Chief Commercial Officer.
🚩 Red Flags
- Significant reduction in workforce (16 employees) to address cash burn issues.
- Departure of two key C-suite executives (COO and CCO).
- High proportion of restructuring costs being paid in equity rather than cash, which may indicate liquidity constraints.
- Risk factor warning regarding potential litigation from employee terminations.
📋 Key Facts
- Workforce reduction involves the departure of 16 employees effective January 31, 2024.
- The reduction aims to decrease annual cash burn by approximately 50%.
- Chief Operating Officer John Sieckhaus and Chief Commercial Officer Gray Fleming are departing their executive roles.
- Total estimated aggregate costs for the reduction are approximately $919,249.
- Estimated costs include $578,636 in retention bonuses and $205,325 in consulting services, primarily paid in equity.
- Departing executives will remain as consultants: Fleming ($138,667 in equity over 4 months) and Sieckhaus ($48,533 in equity over 2 months).
BioSig Technologies, Inc. has implemented a 1-for-10 reverse stock split to consolidate its common stock. The split is effective as of February 1, 2024, and the adjusted shares will begin trading on the Nasdaq Capital Market on February 2, 2024.
🚩 Red Flags
- Reverse stock split (often used to maintain minimum bid price requirements for exchange listing).
📋 Key Facts
- Reverse stock split ratio: 1-for-10.
- Effective date/time: February 1, 2024, at 4:05 p.m. ET.
- Impact on shares outstanding: Reduction from approximately 93,344,435 shares to approximately 9,334,636 shares.
- New CUSIP number: 09073N300.
- Trading symbol remains 'BSGM' on the Nasdaq Capital Market.
- Fractional shares will be rounded up to the next whole number; no fractional shares issued.
BioSig Technologies, Inc. announced a workforce reduction via a press release on January 30, 2024. The filing is submitted under Item 7.01 to provide Regulation FD disclosure regarding the announcement.
🚩 Red Flags
- Workforce reduction often indicates cost-cutting measures due to liquidity constraints or declining revenue in micro-cap biotech firms.
📋 Key Facts
- The company issued a press release announcing a workforce reduction on January 30, 2024.
- The information was furnished under Item 7.01 rather than filed, limiting liability under Section 18 of the Exchange Act.
- Executive Chairman Kenneth L. Londoner signed the report.
BioSig Technologies, Inc. entered into a Securities Purchase Agreement to sell 2,607,170 shares of common stock and warrants to accredited/institutional investors for gross proceeds of $1,040,000.11.
🚩 Red Flags
- Significant dilution: Issuance of over 2.6 million shares plus warrants for a relatively small capital raise.
- Warrant exercise price ($0.3364) is below the current share purchase price ($0.3989), indicating potential downward pressure upon exercise.
- Small-cap financing: The total proceeds of ~$1M are minimal, suggesting the company may be facing liquidity constraints requiring frequent small-scale dilutive raises.
📋 Key Facts
- Date of agreement: January 12, 2024
- Total shares sold: 2,607,170 common stock shares
- Warrants issued: Warrants to purchase up to 1,303,585 shares of Common Stock
- Share purchase price: $0.3989 per share
- Warrant exercise price: $0.3364 per share
- Gross proceeds: $1,040,000.11
- Warrants become exercisable six months after issuance and expire in 5.5 years
- Offering conducted under Section 4(a)(2) and Regulation D (Rule 506)
BioSig Technologies, Inc. has regained compliance with Nasdaq's minimum Market Value of Listed Securities (MVLS) requirement. The company successfully met the $35 million MVLS threshold for 10 consecutive business days ending January 4, 2024.
🚩 Red Flags
- Historical delisting risk due to failure to meet minimum Market Value of Listed Securities (MVLS) requirements.
📋 Key Facts
- The Company was previously notified on December 19, 2023, that it failed to meet the minimum MVLS of $35,000,000 required for Nasdaq Capital Market listing.
- A compliance period was granted until June 17, 2024.
- As of January 5, 2024, the Company's MVLS remained at or above $35,000,000 for 10 consecutive business days (Dec 20, 2023 – Jan 4, 2024).
- Nasdaq has confirmed that the compliance matter is now closed.